LCLAT1

Across TCGA pan-cancer cohorts, LCLAT1 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated LCLAT1 data layer compared with 27 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher LCLAT1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated LCLAT1 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

PDAC, CCRCC, and HNSC are the cancer types where LCLAT1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	II,III,IV	0.244	0.465	.005	27	view →
CCRCC	OS	Median	IV	0.123	0.785	.009	21	view →
HNSC	DFS	Tertile	II,III,IV	0.875	0.651	.014	10	view →
UCEC	DFS	Quartile	All	0.842	1.000	.034	8	view →
LSCC	OS	Quartile	All	0.836	0.952	.017	8	view →
LUAD	DFS	Quartile	All	0.530	0.831	.011	6	view →
GBM	OS	Quartile	All	0.750	1.000	.012	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

LCLAT1–PDAC (DFS)

Open the PDAC breakdown →